AMI - Acute Mesenteric IschemiaNCT05390658
Risk Factors Analysis for Acute Myocardial Infarction Patients
An observational study of AMI - Acute Mesenteric Ischemia and Extracorporeal Membrane Oxygenation Complication, run by Genglong Liu at 1 site in China.
Trial summary
ECMO has been used to save the lives of many critically ill patients with cardiorespiratory dysfunction as important rescue therapy. Though the proportion of ECMO applied to this population has been increasing year by year, clinical outcomes of AMI remain poor with high in-hospital mortality. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- AMI - Acute Mesenteric Ischemia, Extracorporeal Membrane Oxygenation Complication
- What is being tested?
- Not application
- How many people
- 80 participants
- Where
- 1 siteChina
- Study dates
- 11 Jan 2020to 12 Jan 2023
- How long will I take part?
- 2 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: I. Clinical symptoms: the typical angina pectoris symptoms of acute myocardial infarction are compressive pain in the precardiac area and the back of the sternum, accompanied by sweating, a sense of dying, and a sense of suffocation. Taking nitroglycerin tablets or quick-effect Xusuxin pills cannot alleviate the symptoms. 2. Typical ECG manifestations, such as pathological Q wave, ST-segment elevation, or pathological ST-segment depression, have corresponding lead changes. 3. Increased myocardial enzymes, including CK, CK-MB, and troponin, etc. The diagnosis of acute myocardial infarction can be made with two of these three indicators.
Who may be able to join
- Clinical diagnosis of Alzheimer's Disease Age more than 18
Who cannot join
- Life expectancy <1 year Prolonged cardiac arrest before VA-ECMO therapy (>60 min) Iatrogenic myocardial infarction secondary to a percutaneous coronary intervention VA-ECMO implanted in another center before admission
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Genglong Liu
Guangzhou, State..., 510080
Genglong Liu, +8615626405844, lglong3@mail2.sysu.edu.cn
About this study
Official title: Clinical Features and Risk Factors Analysis for Acute Myocardial Infarction Patients Received ECMO
ECMO has been used to save the lives of many critically ill patients with cardiorespiratory dysfunction as important rescue therapy. Though the proportion of ECMO applied to this population has been increasing year by year, clinical outcomes of AMI remain poor with high in-hospital mortality. Thus, it is necessary to characterize clinical features and investigate potentially modifiable factors contributing to outcomes of AMI patients who received ECMO treatment.
- Being tested
- Not application
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Not applicationOther
Not application
| Study group | Role | What they receive |
|---|---|---|
| Survival | Not described Receives: Other: Not application | |
| Death | Not described Receives: Other: Not application |
What is being measured
The primary outcome is the main question the study is designed to answer.
Survival rate
Survival information from ICU entry to ICU exit
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2022
- Study start11 Jan 2020
- Primary completion12 Nov 2022 (estimated)
- Study completion12 Jan 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AMI - Acute Mesenteric IschemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 80 participants (estimated)
- Target duration
- 2 Months
Sponsor and investigators
- Lead sponsor
- Genglong Liu
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Genglong Liu, First Affiliated Hospital, Sun Yat-Sen University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05390658
- Sponsor's protocol ID
- ECOM
- Status last verified
- May 2022
- First submitted
- 16 May 2022
- Last updated
- 25 May 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Features and Risk Factors Analysis for Acute Myocardial Infarction Patients Received ECMO
- ClinicalTrials.gov ID
- NCT05390658
- Acronym / sponsor ID
- ECOM
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Genglong LiuUniversity, hospital or other
- Study start
- 11 Jan 2020 (actual)
- Primary completion
- 12 Nov 2022 (estimated)
- Study completion
- 12 Jan 2023 (estimated)
- First posted
- 25 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
ECMO has been used to save the lives of many critically ill patients with cardiorespiratory dysfunction as important rescue therapy. Though the proportion of ECMO applied to this population has been increasing year by year, clinical outcomes of AMI remain poor with high in-hospital mortality. Thus, it is necessary to characterize clinical features and investigate potentially modifiable factors contributing to outcomes of AMI patients who received ECMO treatment.
Study design
- Observational model
- Cohort
- Time perspective
- Other
- Target follow-up
- 2 Months
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Survival | – | Other: Not application |
| Death | – | Other: Not application |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- I. Clinical symptoms: the typical angina pectoris symptoms of acute myocardial infarction are compressive pain in the precardiac area and the back of the sternum, accompanied by sweating, a sense of dying, and a sense of suffocation. Taking nitroglycerin tablets or quick-effect Xusuxin pills cannot alleviate the symptoms. 2. Typical ECG manifestations, such as pathological Q wave, ST-segment elevation, or pathological ST-segment depression, have corresponding lead changes. 3. Increased myocardial enzymes, including CK, CK-MB, and troponin, etc. The diagnosis of acute myocardial infarction can be made with two of these three indicators.
Key inclusion criteria (1 listed)
- Clinical diagnosis of Alzheimer's Disease Age more than 18
Key exclusion criteria (1 listed)
- Life expectancy <1 year Prolonged cardiac arrest before VA-ECMO therapy (>60 min) Iatrogenic myocardial infarction secondary to a percutaneous coronary intervention VA-ECMO implanted in another center before admission
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Not applicationNot application | Other | Death, Survival |
Primary outcome
Survival rate
Time frame: 1 month
Survival information from ICU entry to ICU exit
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2022.
- Individual participant dataSharing planned: Undecided
Related trials for AMI - Acute Mesenteric Ischemia
Recruiting
Evaluation of the Discriminative Abilities of Biomarkers for the Diagnosis of Acute Mesenteric Ischemia Compared With Another Similar Clinical Presentation: a Pilot Study
Acute Mesenteric Ischemia
Active, not recruiting
ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery
Acute Mesenteric Ischemia
RecruitingObservational study
Predictors of Transmural Non-Occlusive Mesenteric Ischemia in ICU Patients With Suspected Acute Mesenteric Ischemia
Non-Occlusive Mesenteric Ischaemia (NOMI), Acute Mesenteric Ischemia
RecruitingObservational study
Assessment of Quality of Life After Acute Mesenteric Ischemia
Acute Mesenteric Ischemia
Recruiting
Searching Biomarkers of Acute Intestinal Ischemic Injuries
Acute Mesenteric Ischemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of AMI - Acute Mesenteric Ischemia and Extracorporeal Membrane Oxygenation Complication, run by Genglong Liu at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 25 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Survival rate (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2022.